Page 461«..1020..460461462463..470480..»

Rare-disease foundation backs regenerative research – OutSourcing-Pharma.com

Posted: Published on December 8th, 2020

CureDuchenne is a global nonprofit honed in on discovering a cure for Duchenne muscular dystrophy (DMD). Its funding arm, CureDuchenne Ventures, is investing in regenerative medicine firm Mesentech, as part of a joint funding collaboration with the Charles H Hood Foundation (which seeks to advance early-stage research for pediatric conditions) Continue reading →

Posted in Muscular Dystrophy Treatment | Comments Off on Rare-disease foundation backs regenerative research – OutSourcing-Pharma.com

Duchenne Muscular Dystrophy Treatment Market Massive Growth in Globally with Top Key Players: SUMMIT Therapeutics Plc., PTC Therapeutics, BioMarin…

Posted: Published on December 8th, 2020

Duchenne muscular dystrophy (DMD) is a genetic disorder characterized by progressive muscle degeneration and weakness. Continue reading →

Posted in Muscular Dystrophy Treatment | Comments Off on Duchenne Muscular Dystrophy Treatment Market Massive Growth in Globally with Top Key Players: SUMMIT Therapeutics Plc., PTC Therapeutics, BioMarin…

Everything You Need to Know About Genome Editing – Interesting Engineering

Posted: Published on December 8th, 2020

Gene editing still has a ways to go. But someday, this medical tool could be used to treat a wide range of degenerative diseases. Every cell in your body has around 3 billion base pairs of DNA code inside it Continue reading →

Posted in Muscular Dystrophy Treatment | Comments Off on Everything You Need to Know About Genome Editing – Interesting Engineering

NF-kappa B Inhibitors Therapeutics Pipeline Analysis of 80+ Companies – GlobeNewswire

Posted: Published on December 8th, 2020

December 08, 2020 04:34 ET | Source: DelveInsight Business Research LLP Los Angeles, Dec. 08, 2020 (GLOBE NEWSWIRE) -- NF-kappa B Inhibitors Therapeutics Pipeline Analysis of 80+ Companies The Key Players involved in developing the NF-kappa B Inhibitors therapies are AnGes MG, Complexa, Accendatech, Serenex, OncoViRx, Novo Nordisk, Profectus Biosciences, Mitsubishi Tanabe Pharma, ImmuneTarget, Merck Serono, EntreChem, Link Health Group and others. NF-kappa B Inhibitors Pipeline Insight, 2020 report by DelveInsight provides extensive insights around 80+ Companies and 80+ Pipeline Drugs based on NF-kappa B Inhibitors pipeline landscape Continue reading →

Posted in Muscular Dystrophy Treatment | Comments Off on NF-kappa B Inhibitors Therapeutics Pipeline Analysis of 80+ Companies – GlobeNewswire

VASCEPA (Icosapent Ethyl)-Related Scientific Findings to Be Presented at National Lipid Association (NLA) Scientific Sessions 2020 – BioSpace

Posted: Published on December 8th, 2020

Amarin-Supported Research and Analyses from Academic Collaborators to Be Featured in Two Late Breaker and Six e-Poster Presentations, Including Encore of REDUCE-IT EPA, Primary Results of the VASCEPA COVID-19 CardioLink-9 Trial, and Mechanism of Action Insights DUBLIN, Ireland and BRIDGEWATER, N.J., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that scientific findings that add to the growing body of knowledge on VASCEPA (icosapent ethyl) will be presented during the National Lipid Association (NLA) Scientific Sessions 2020, being held virtually from December 10 12, 2020 Continue reading →

Posted in Clinical Cardiology | Comments Off on VASCEPA (Icosapent Ethyl)-Related Scientific Findings to Be Presented at National Lipid Association (NLA) Scientific Sessions 2020 – BioSpace

Gossamer Bio to Host Webcast Focused on GB002 and Pulmonary Arterial Hypertension (PAH) on December 15, 2020 – Business Wire

Posted: Published on December 8th, 2020

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will host a conference call and webcast for investors and analysts on Tuesday, December 15, 2020 at 11:00am ET to discuss GB002, its inhaled PDGFR inhibitor, for the treatment of pulmonary arterial hypertension (PAH) Continue reading →

Posted in Clinical Cardiology | Comments Off on Gossamer Bio to Host Webcast Focused on GB002 and Pulmonary Arterial Hypertension (PAH) on December 15, 2020 – Business Wire

Deaths due to mitral valve disease in U.S. increased in last six years, after 14 years of continuous decline – The Mix

Posted: Published on December 8th, 2020

A study conducted by UAB investigators has outlined that deaths due to mitral regurgitation are increasing in the United States since 2012, after a continuous decline for 14 years. Continue reading →

Posted in Clinical Cardiology | Comments Off on Deaths due to mitral valve disease in U.S. increased in last six years, after 14 years of continuous decline – The Mix

New Tool May Improve Prediction and Discrimination of Suspected Obstructive CAD – The Cardiology Advisor

Posted: Published on December 8th, 2020

A novel tool in which clinical risk factors and coronary artery calcium score (CACS) are added to standard pre-test probability (PTP) modeling was found to improve risk prediction in suspected obstructive coronary artery disease (CAD), according to a study published in the Journal of the American College of Cardiology. Continue reading →

Posted in Clinical Cardiology | Comments Off on New Tool May Improve Prediction and Discrimination of Suspected Obstructive CAD – The Cardiology Advisor

Increased ASCVD Risk With Inflammatory Bowel Disease Merits Team-Based Care – TCTMD

Posted: Published on December 8th, 2020

Inflammatory bowel disease (IBD) has thus far been overlooked as a contributor to atherosclerotic cardiovascular disease (ASCVD) risk, urges a new review that outlines whats known about the overlap between the two and offers advice on next steps. While the inflammatory hypothesis for cardiovascular disease has recently gained tractionwhat with positive results from CANTOS, COLCOT, and LoDoCo2data specific to IBD are scarce, authors say Continue reading →

Posted in Clinical Cardiology | Comments Off on Increased ASCVD Risk With Inflammatory Bowel Disease Merits Team-Based Care – TCTMD

4D Molecular Therapeutics Strengthens Leadership Team with Key Appointments in Clinical Research and Development – BioSpace

Posted: Published on December 8th, 2020

4DMT has made tremendous progress since the close of our Series C financing. We have advanced product candidates across our key therapeutic areas of ophthalmology, cardiology and pulmonology, including the initiation of the clinical programs for 4D-110 and 4D-125 in ophthalmology, and 4D-310 for the treatment of Fabry disease, said David Kirn, M.D., co-founder and chief executive officer of 4DMT. With the addition of Robert Fishman, Raphael Schiffmann and Robert Kim to our clinical R&D leadership team, 4DMT gains not only extensive experience in clinical development and translational medicine, but also unique and specific experience within each of the initial 4DMT therapeutic areas. Continue reading →

Posted in Clinical Cardiology | Comments Off on 4D Molecular Therapeutics Strengthens Leadership Team with Key Appointments in Clinical Research and Development – BioSpace

Page 461«..1020..460461462463..470480..»